Lung Cancer News

CancerConnect lung cancer news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of lung cancer research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of lung cancer treatment and survivorship.

Share

Lung Cancer News


Another Study Confirms That Daily Aspirin Lowers Risk of Colorectal & Other GI Tract Cancers (May 9, 2016)

The regular use of aspirin significantly reduces the overall risk of cancer, especially colorectal and other gastrointestinal tract cancers, according to a study published in JAMA Oncology.1 The recent... Continue Reading

Xalkori® Approved for Lung Cancer with ROS-1 Gene Alterations (March 29, 2016)

The United States Food and Drug Administration (FDA) approved Xalkori (crizotinib) as treatment for patients with advanced non-small cell lung cancer (NSCLC) whose cancer has an alteration within the ROS-1... Continue Reading

Lung Cancer Advances: Precision Medicine and Immunotherapy Make a Difference (March 1, 2016)

Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged... Continue Reading

Immune-Targeting Drug Combo Shows Promise for Non-Small Cell Lung Cancer Patients, Say Moffitt Cancer Center Researchers (February 22, 2016)

Lung cancer is the most common cause of cancer-related deaths in the United States resulting in more than 158,000 deaths each year. With a 5-year survival rate at only 18 percent, the development of new... Continue Reading

Important Step Toward Widespread Use Of Low-Dose Computed Tomography Lung Cancer Screening In The United States (January 29, 2016)

Excerpted from: Advances in Cancer Research And Treatment: 2015 Year In Review One strategy for reducing the death rate from lung cancer is to increase the rate of early detection so that cancers are found... Continue Reading

Patients With Early-Stage Melanoma And Lung Cancer Among Those Standing To Benefit From Immunotherapy (January 29, 2016)

Excerpted from: Advances in Cancer Research And Treatment: 2015 Year In Review Immunotherapy, a type of biological therapy, is among the most promising areas of cancer treatment advances. This approach... Continue Reading

Encouraging News For Patients With Treatment-Resistant Lung Cancer (January 29, 2016)

Excerpted from: Advances in Cancer Research And Treatment: 2015 Year In Review Although lung cancer is still a deadly disease—responsible for more than 150,000 deaths each year in the United States alone—there... Continue Reading

Alecensa™ Approved for the Treatment of Recurrent ALK-Positive Lung Cancer (December 24, 2015)

The FDA approved another inhibitor of anaplastic lymphoma kinase (ALK) for treatment of non-small cell lung cancer (NSCLC) today, further expanding precision treatment options. Alecensa™ (Alectinib)... Continue Reading

Novel Precision Medicine Tagrisso Approved for Treatment of Lung Cancer (November 19, 2015)

The United States Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the treatment of lung cancer with the epidermal growth factor receptor (EGFR) T790M mutation. The indication... Continue Reading

New Lab Test Enables Precision Treatment for Lung Cancer (November 13, 2015)

The complementary laboratory test that measures PD-L1 levels among patients with lung cancer who are to receive treatment with Opdivo® (nivolumab), is now available for commercial use and can help guide... Continue Reading

More Lung Cancer News

Latest Lung Cancer News By Stage


General

Lung Cancer Advances: Precision Medicine and Immunotherapy Make a Difference (March 1, 2016)

Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged to match a person’s genetic make­up or a tumor’s... Continue Reading

Alecensa™ Approved for the Treatment of Recurrent ALK-Positive Lung Cancer (December 24, 2015)

The FDA approved another inhibitor of anaplastic lymphoma kinase (ALK) for treatment of non-small cell lung cancer (NSCLC) today, further expanding precision treatment options. Alecensa™ (Alectinib) is indicated for advanced, metastatic, ALK-positive... Continue Reading

New Lab Test Enables Precision Treatment for Lung Cancer (November 13, 2015)

The complementary laboratory test that measures PD-L1 levels among patients with lung cancer who are to receive treatment with Opdivo® (nivolumab), is now available for commercial use and can help guide more precise therapy for lung cancer. Lung cancer... Continue Reading

Updated Results Confirm Improved Survival with Opdivo® in Lung Cancer (November 10, 2015)

Longer follow-up confirms the survival benefit with the use of the PD-1 inhibitor, Opdivo® (nivolumab), compared to the chemotherapy agent, docetaxel, among patients with recurrent non-small cell lung cancer (NSCLC). These results were recently published... Continue Reading

Opdivo® Receives Expanded Approval for an Additional Type of Lung Cancer (October 19, 2015)

The United States Food and Drug Administration (FDA) has expanded the approval of Opdivo® (nivolumab) for the treatment of non-squamous, non-small cell lung cancer. Non-small cell lung cancer (NSCLC), the most common type of lung cancer, is divided into... Continue Reading

More General

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS